Go to
JCI Insight
Citations to this article
Abstract
Pretreatment of L5178Y murine leukemia cells with uracil arabinoside (ara-U) enhances the cytotoxicity of cytosine arabinoside (ara-C). This effect is mediated by the cytostatic effect of ara-U, which causes a delay of cell progression through S-phase. Consequently, the specific activity of enzymes that peak during S-phase increases, and deoxycytidine kinase increases 3.6-fold over untreated controls. This allows enhanced anabolism of ara-C to nucleotides, as well as increased incorporation into DNA with ultimate synergistic cytotoxicity. It is postulated that the systemic metabolism of high-dose ara-C to sustained high levels of ara-U in patients with acute leukemia may enhance the activity of subsequent doses of ara-C, and thus contribute to a means for pharmacologic self-potentiation, contributing to the unique therapeutic activity of high-dose ara-C.
Authors
J L Yang, E H Cheng, R L Capizzi, Y C Cheng, T Kute
Total citations by year
Citation information
Citations to this article (27)
| Title and authors | Publication | Year |
|---|---|---|
|
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action
EJ Derissen, JH Beijnen |
Clinical Pharmacokinetics | 2020 |
|
Simultaneous determination of 1-β-D-Arabinofuranosylcytosine and two metabolites, 1-β-D-Arabinofuranosyluracil and 1-β-D-Arabinofuranosylcytosine triphosphate in leukemic cell by HPLC-MS/MS and the application to cell pharmacokinetics
D Liang, W Wang, X Jiang, Y Shiliang |
Journal of Chromatography B | 2014 |
|
Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of 1-β-D-Arabinofuranosyluracil in human plasma and application to therapeutic drug monitoring in patient with leukemia
C Liao, S Chang, S Hu, Z Tang, G Fu |
Journal of Pharmaceutical and Biomedical Analysis | 2013 |
|
Advances in Cancer Research
M Lemaire, S Deleu, ED Bruyne, EV Valckenborgh, E Menu, K Vanderkerken |
Advances in Cancer Research Volume 110 | 2011 |
|
Deoxynucleoside Analogs In Cancer Therapy
GJ Peters |
2007 | |
|
Acute Leukemias VII
W Hiddemann, T Büchner, B Wörmann, J Ritter, U Creutzig, M Keating, W Plunkett |
1998 | |
|
Pharmacokinetics of High-Dose Cytarabine and its Deamination Product-A Reappraisal
M Burk, A Heyll, M Arning, M Volmer, K Fartash, W Schneider |
Leukemia & Lymphoma | 1997 |
|
Guanosine Potentiates the Antiproliferative Effect of Cytosine-β-D-Arabinofuranoside in Melanoma Cell Lines
Y Sidi, C Panet, A Cyjon, E Fenig, E Beery, J Nordenberg |
Cancer Investigation | 1993 |
|
Modulation of the cellular pharmacokinetics of ara-CTP in human leukemic blasts by dipyridamole
JL Yang, JC White, RL Capizzi |
Cancer Chemotherapy and Pharmacology | 1992 |
|
Deoxypyrimidine-induced inhibition of the cytokinetic effects of 1-?-d-arabinofuranosyluracil
B Chandrasekaran, TE Kute, RL Capizzi |
Cancer Chemotherapy and Pharmacology | 1992 |
|
Phenotypic analysis of 1-B-d-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response
W Kreis, M Lesser, DR Budman, Z Arlin, L DeAngelis, P Baskind, EJ Feldman, S Akerman |
Cancer Chemotherapy and Pharmacology | 1992 |
|
Biochemical Pharmacology of Blood and Bloodforming Organs
JW Fisher |
1992 | |
|
Antimetabolites
RL Capizzi, JC White, DJ Fernandes |
Baillière's Clinical Haematology | 1991 |
|
Metabolism of pyrimidine analogues and their nucleosides
GC Daher, BE Harris, RB Diasio |
Pharmacology & Therapeutics | 1990 |
|
Biochemical modulation of cytosine arabinoside
S Grant |
Pharmacology & Therapeutics | 1990 |
|
Enhanced retention of cytosine arabinoside and its metabolites and synergistic cytotoxicity by sequential treatment with dipyridamole in L5178Y leukemia
JL Yang, JC White, RL Capizzi |
Cancer Chemotherapy and Pharmacology | 1990 |
|
The disposition of cytosine arabinoside and its metabolite after single doses to rabbits
CL Zimmerman |
Biopharmaceutics & Drug Disposition | 1990 |
|
The effect of ara-C-induced inhibition of DNA synthesis on its cellular pharmacology
LM Wang, JC White, RL Capizzi |
Cancer Chemotherapy and Pharmacology | 1990 |
|
Determination of 3H-labelled cytosine arabinoside and eight metabolites in cell extracts by high-performance liquid chromatography and scintillation spectrometry
LM Wang, CN Woodward, JC White, RL Capizzi |
Journal of Chromatography B: Biomedical Sciences and Applications | 1989 |
|
The pharmacologic basis for the efficacy of high-dose Ara-C and sequential asparaginase in adult acute myelogenous leukemia
RL Capizzi, C White |
The Yale journal of biology and medicine | 1988 |
|
Effect of cytosine arabinoside on the human immunosystem: metabolism and cytotoxicity studied with mitogen-stimulated normal blood lymphocytes in vitro
JA Vilpo, T Veromaa, E Eerola |
International Journal of Immunopharmacology | 1988 |
|
Phase I–II trial of acivicin in adult acute leukemia
BL Powell, JB Craig, RL Capizzi, F Richards |
Investigational New Drugs | 1988 |
|
High-dose cytosine arabinoside: pharmacological and clinical aspects
WG Peters, LP Colly, R Willemze |
Blut Zeitschrift für die Gesamte Blutforschung | 1988 |
|
Pharmacology of Combination Chemotherapy of Cytosine Arabinoside (Ara-C) and Uracil Arabinoside (Ara-U) or Tetrahydrouridine (THU) against Murine Leukemia L1210/0 in Tumor-Bearing Mice
VI Avramis, W Powell |
Cancer Investigation | 1987 |
|
Acute Leukemias
T Büchner, G Schellong, W Hiddemann, D Urbanitz, J Ritter |
1987 | |
|
Cancer Chemotherapy by Infusion
JJ Lokich |
1987 | |
|
DOSE-RELATED PHARMACOLOGIC EFFECTS OF HIGH DOSE ARA-C AND ITS USE IN COMBINATION WITH ASPARAGINASE FOR THE TREATMENT OF PATIENTS WITH ACUTE NON-LYHPHOCYTIC LEUKEMIA*
RL Capizzi, BL Powell, MR Cooper, JP Rathmell, JC White, HB Muss, F Richards, DV Jackson, JJ Stuart, DR White, PJ Zekan, JM Cruz, CL Spurr |
Scandinavian Journal of Haematology | 1986 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)